Board of Directors
Chairman of 2cureX AB and 2cureX A/S
Tonni Bülow-Nielsen has extensive medical device and life science experience as Partner (until 2020 he was also Managing Partner and Senior Vice President in the executive leadership group) through more than 16 years in EIFO (Export and Investment Fund of Denmark), previously Vækstfonden. Today Tonni is a Partner in the Medtech and Lifescience team in EIFO for venture investments and manage a significant portfolio of investments through Board positions, value creation and transactions. Before joining Vækstfonden in 2007, Tonni was founder and CEO of DanMed A/S and Nordic Medical Group A/S from 2002-2007.
Tonni lived and worked in USA 1996-2002 as SVP for USA and President of ELA Medical (Canada & South America), a part of the Sanofi Group, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan). Before this he was Business Unit Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical.
His educational background is medical engineering, and he holds an executive MBA from the Scandinavian International Management Institute.
Tonni has been the chairman of 2cureX AB since 2023 and 2cureX A/S since 2023.
Other board assignments
Evosep, Reapplix, TeesuVac, Microshade, Cathvision, Arcedi Biotech and ILS Denmark.
Independence
Independent of management, the company and major shareholders.
Board Member of 2cureX AB and 2cureX A/S
Povl-André Bendz (B. 1962) is an Executive and Investor.
Povl-André has a M.Sc. from Copenhagen Business School and long experience from commercial and financial assignments within Life Science. Povl-André is presently CEO and boardmember of Seahouse Capital, part of Spotlight Group. Povl-André has previously held C-level positions in DELTA Technology, Upfront Chromatography and other international companies, and has long experience of board work.
Povl-André has been a board member of 2cureX A/S since 2014 and Chairman of the board of 2cureX AB from 2017 to 2023.
2cureX share ownership and warrants
194 033 shares
Other board assignments
Audientes, chairman, listed on Nasdaq First North Growthmarket Copenhagen, IMATRA Holding S.A., chairman and Thornæs Destilleri, member, Agilco, member.
Independence
Independent of management, the company and major shareholders
Board Member of 2cureX AB and 2cureX A/S
Camilla Huse Bondesson (B. 1958) is an Executive and board member in medtech companies.
Camilla has an Executive MBA from Stockholm University. Currently, she is Chairman of the Board of Gradientech AB, Immuneed AB and TdB Labs AB. Camilla has over thirty years of international operational and strategic experience from senior positions at companies in the biotechnology field, including as General Manager of Behring Diagnostica AB, International Product Manager for Biacore, Marketing Director of Amersham Biosciences (current GE Healthcare Life Sciences) and VP Marketing for Gyros AB. Since 2004 Camilla has been working as a consultant and partner at Conlega, a consulting company focusing on Life Science. Camilla has been a board member of 2cureX AB since 2019 and 2cureX A/S since 2019.
2cureX share ownership and warrants
33 472 shares
Other board assignments
Gradientech AB
Immuneed AB
TdB Consultancy AB
Independence
Independent of management, the company and major shareholders
Board member and CSO/Deputy CEO of 2cureX AB and 2cureX A/S
Ole Thastrup (B. 1953) is co-founder of 2cureX. He has been a board member of 2cureX since its inception.
Ole holds a MSc in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also a Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg’s biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fisher BioImage) which was spun out from Novo Nordisk A/S. Ole is the inventor in several families of globally issued patents. He had advised several venture funds and is a member of granting institutions (e.g. Novo Nordisk Foundation).
2cureX share ownership and warrants
4 156 134 shares via own company
Other board assignments
OT311 APS
Independence
Affiliated to management, the company, and major shareholders
Board member of 2curex A/S and 2curex AB.
Michael is a biologist and chemist from Mainz University in Germany. His professional career started in microbiology and cell diagnostics at E. Merck Darmstad. He next moved to Bayer Diagnostics as Marketing Director for Haematology and Lab Information Systems, leading the company to a top position in the market. As Regional Director in South-East Asia in 1993, based out of Singapore, he grew the company’s turnover by a factor of five in the following four years.
He joined Sysmex Corporation in 1997 to lead the operations in EMEA. Over the next twenty years he raised the company to its position of European market leader position in lab haematology, coagulation and urinalysis, with sales of some 0.5 billion EUR. In the process, he established and was Director of most of the close to thirty Sysmex affiliates in EMEA.
In his last years at Sysmex he was Executive VP of Sysmex Corporation, Kobe, Japan, in charge of New Business Development, where he led three major acquisition projects and defined the company’s global strategy in the Oncology arena.
2curex share ownership and warrants:
40 000 warrants
Independence:
Independent of Management, the company and major shareholders
Board Member of 2cureX AB and 2cureX A/S
Michel Klimkeit is an economist by training, with an MBA from Hamburg and Rotterdam. He started his professional career as an asset manager, followed by a position at a Germany-based Fintech. In 2016 he joined Warburg Invest, a German institutional asset manager where he was in charge of their European small & midcap equity strategy. Later, in 2020, he joined Auretas Family Trust, a multifamily office where he manages the companies’ private markets and private equity strategies.
Michel joined the 2cureX Board of Directors in February 2023.